
GMT Genomics S.A.
Research and experimental development in natural sciences and engineering
Overview
Gmt Genomics is the creator of Genomtec ID, a mobile platform for genetic diagnostics at the point of patient care. They have developed the GenomtecID Respiratory Panel 5-Plex (RP5-PLEX), which is designed to detect viruses and bacteria responsible for respiratory tract infections and is the only solution of its kind in Europe. The company is also involved in technology trials and M&A efforts in Asia related to their diagnostic devices.
Financials
From the notes
| Current income tax (CIT due) | $0 | |
| Profit allocation | Loss to be covered | |
| Loans and borrowings | $161,092 | |
| Capital expenditure | $18,210 | |
| R&D costs | $147,583 | |
| Contingent liabilities | Yes |
Filing timeliness
1 of 1 financial statements was filed late (for 2025, 62 days late). All were audited by a statutory auditor.
- 202515/09/2026
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.
Results vs industry
News

Miron Tokarski to speak at the upcoming webinar „Meeting the Challenges and Unlocking the Potential of Point-of-Care Molecular Diagnostics”

Another patent granted. Another step in building global protection for Genomtec's molecular diagnostics technology

Genomtec secures PLN 11 million from share issue to finalise global M&A strategy and commercialise breakthrough Genomtec ID and OncoSNAAT® technologies

Start of public share offering of Genomtec to raise funds for completing the M&A process and commercialising Genomtec ID and OncoSNAAT® technologies

Genomtec plans share issue; proceeds will support the M&A process and commercialisation of projects. Company signed investment agreement with key shareholder.

As part of the M&A process, Genomtec prepares to test its technology with potential partners in Asia
Industry
Offer
- Diagnostic equipment
- RT-LAMP diagnostic kit
- SARS-CoV-2 diagnostic test
- Molecular diagnostics
- Research and development in genetic diagnostics
Websites
The site is available in: Polish and English. The site targets these markets: United States.
- genomtec.comStrona główna - GenomtecWordPress 6.9Yoast SEOWWPMLApache
Job offers
The company lists many job openings on its own careers page: genomtec.com/o-nas. The first ones are below.
Authorized Representatives
Manner of representation
Each member of the management board independently.
Supervisory board
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
| 1,100,000 | $297,136.68 | 100% |
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2025-11-01.
44 1090 2398 0000 0001 6486 6586
80 1090 2398 0000 0001 6186 7765
26 1090 2398 0000 0001 6486 6619
Debt
No entries in the National Debtors Register (KRZ).
Public aid
No public aid cases recorded in the last 10 years.
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Farmabol sp. z o.o. | $374,904.90 | farmabol.pl | ||
| FREY sp. z o.o. | $244,328.62 | freymedical.eu | ||
| Vitrotest Europe sp. z o.o. | $233,350.77 | vitrotest.pl | ||
| Materials Design, Systems & Devices sp. z o.o. | $129,918.44 | mdsd.pl | ||
| Kamika Instruments sp. z o.o. | $114,049.10 | kamika.pl | ||
| Hagmed sp. z o.o. | $94,318.82 | hagmed.com | ||
| NEVT sp. z o.o. | $64,528.30 | nevt.pl | ||
| Replicon sp. z o.o. | $50,379.75 | replicon.pl | ||
| Amplicon sp. z o.o. | $48,330.99 | amplicon.pl | ||
| Grupa Psychotronics sp. z o.o. | $27,307.51 | psychotronics.pl |
FAQ
Last updated: 2026-09-15